Our findings also are important in that by defining agonistic peptides for both class Ia and class Ib MHC-restricted CD8+ Tregs, we provide a unique biologics or synthetic chemistry opportunity for potential novel therapeutics for IBD. This evidence concerns the gene HLA-C and inflammatory bowel disease.